You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics

    SBC: Neurolux, Inc.            Topic: 101

    Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biol ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Monochromatic 222 nm UV light: Development of a safe, cost-effective technology for the efficient reduction of bacterial and viral infection and transmission

    SBC: EDEN PARK ILLUMINATION, INC.            Topic: NIAID

    Drug resistant bacteria such as MRSA, and airborne-transmitted microbes such as influenza and TB, present significant health issues, with major healthcare and economic consequences. UV light is a well-established highly-efficient anti-microbial modality, effective both against both bacteria and viruses. However it is not possible to use UV sterilization in scenarios where people are present becaus ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: CETYA THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARY The β-hemoglobinopathies are prevalent genetic blood diseases with few treatment options. It is estimate that 7% of the worldandapos;s population carries an abnormal hemoglobin gene with 400,000 infants born annually with a severe life threatening hemoglobinopathy. Drug mediated induction of normal, but developmentally silenced, fetal hemoglobin (HbF) expression reduces anemia and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Developing a peptide-based oral drug to prevent kidney stones

    SBC: Oxalo Therapeutics, Inc.            Topic: 400

    Project Summary/Abstract Kidney stones (KS) are highly prevalent, excruciating, and associated with long term complications of chronic kidney disease (CKD) and end stage renal disease (ESRD). They account for 1.3M ER visits and andgt;$10B of medical costs annually and have a striking recurrence rate of 50% in 5 years and up to 80% in 10 years, reflecting the inadequacies of current interventions. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. 4-(Aminomethyl) benzamides as novel anti-Ebola agents

    SBC: Chicago Biosolutions, Inc.            Topic: NIAID

    Ebola (EBOV) and Marburg (MARV) viruses belong to the Filoviridae family and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction after an incubation period of 4-14 days. Due to safety concerns, these viruses are designated as biosafety level 4 agents. Currently, there is no effective vaccine or therapeutic treatment for filoviral infections in humans. Africa has recen ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Application of PPODA-QT for embolization of aneurysms

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 101

    PROJECT SUMMARY/ABSTRACTA cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain. Often going unnoticed and untreated, an aneurysm can cause a sudden and catastrophic hemorrhage or stroke. Approximately 15 % of patients die from an aneurysm rupture even before receiving medical attention and 25 % of patients die despite medical treatment. Patie ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government